Nov 10,2022

Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

Announcing Tidepool+, the next evolution of the Tidepool Data Platform

Tidepool’s Population Health Dashboard is the centerpiece to an evolution of the Tidepool Data Platform, called Tidepool+. With Tidepool+, Tidepool is introducing a premium offering that includes enhanced security controls like Single Sign-On, tools for direct patient engagement, and our Population Health Dashboard to empower Clinicians to sort, filter, and segment their patient lists based on a number of key factors.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches

DexCom, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design site that illustrate just how unique each person’s diabetes story is.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize

LifeScan today announced results of a new global research study of 793 adults living with Type 2 diabetes and 322 healthcare providers. The study showed people living with diabetes are more motivated to seek a doctor’s advice and take action to manage their condition than healthcare providers may realize, while acknowledging they still face daily challenges. Despite healthcare providers recommending blood glucose management apps to only 25 percent of their patients, 55% of patients who reported having a blood glucose meter that includes an app claimed they use the app regularly.

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

DarioHealth Reports Third Quarter 2022 Financial and Operating Results

DarioHealth Corp. today reported financial results for the third quarter 2022 and provided a corporate and B2B (formerly described as B2B2C) update. Revenues for the third quarter ended September 30, 2022 were $6.6 million, a 17.3% increase from $5.6 million for the third quarter ended September 30, 2021, and an increase of 6.8% from $6.2 million for the for the second quarter of 2022. The increase resulted from higher revenues from the Company's B2B segments, including health plans, employers and providers.

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate milestones. Net loss for the quarter ended September 30, 2022 was $11.4 million, compared to $12.5 million for the same period in 2021. Cash and cash equivalents were $22.3 million on September 30, 2022, compared to $40.6 million on December 31, 2021.

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

Nemaura Medical, Inc. today releases its financial results for the quarter ending September 30, 2022 and provides a business update. Cash and cash equivalents at September 30, 2022 were approximately $10.1 million. The company entered into a term sheet with Eversana to begin strategy development and subsequent launch of the BEATdiabetes program and the Company’s unique daily wear proBEAT™ sensors in the U.S. The launch is expected in the first calendar quarter of 2023 and will target insurers and corporate clients.

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Better Therapeutics to Participate in BTIG Digital Health Forum

Better Therapeutics, Inc. today announced that Frank Karbe, Chief Executive Officer, and Mark Berman, MD, Chief Medical Officer, will participate in a virtual fireside chat at the BTIG Digital Health Forum on Monday, November 21, 2022, at 2:00 p.m. ET / 11:00 a.m. PT. Better Therapeutics management will be available for virtual one-on-one meetings with investors during the conference.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Teladoc Health Reaches 50 Million Visit Milestone

Teladoc Health announced today that it has surpassed 50 million visits delivered by the company’s global network of clinicians. This milestone is in addition to the millions of visits enabled by its enterprise virtual care platform for hospital and health system clients. The percentage of individuals enrolled in chronic condition management solutions using two or more programs continues to grow, from 13% in 2020, to 24% in 2021, to 34% in 2022.

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Insulet issues device correction on Omnipod 5 controller due to charging issue

Insulet announced a medical device correction for its Omnipod 5 automated insulin delivery system. Insulet’s correction relates to an issue with the Omnipod 5 controller’s charging port and cable. The correction does not impact the Omnipod 5 pod, the previous-generation Omnipod Dash and Omnipod, or compatible Android smartphone devices with the Omnipod 5 app installed.

PRODUCT

#insulin pump

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES